Alzheimer's Disease Trial, By Invitation NCT02414178 Sponsor: Washington University School of Medicine Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, By Invitation

NCT02414178
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Participants must already be enrolled in the Dominantly Inherited Alzheimer's Network (DIAN) Performance Site study or the DIAN Extended Registry.
  • Participants must be male or female and at least 18 years old.
  • Participants must have either normal thinking and memory function, or only mild dementia, as determined by a clinical assessment.
  • Participants must be able and willing to go through brain scans (MRI or CT, and PET scans) and receive an injection of a radioactive tracer (those who cannot have an MRI will have a CT scan instead).
  • Women who have not yet gone through menopause must take a urine pregnancy test within 24 hours before receiving the study drug, and the drug will only be given if the test result is negative.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have any health condition that, in the investigator's opinion, could increase risk, make it hard to get through the study procedures, or affect the results (for example, severe chronic back pain that might prevent lying still during scans).
  • People who are considered unlikely to be able to complete the imaging procedures for any reason.
  • People who have a high risk of a serious heart rhythm problem called Torsades de Pointes, or who are taking medications known to affect the heart's electrical activity (prolong the QT interval).
  • People who have an allergy or sensitivity to the imaging agent F 18 T807 or any of its ingredients.
  • People who have any reason they cannot safely have a PET, PET-CT, or MRI scan (for example, having certain electronic medical devices implanted, or being unable to lie still for extended periods).
  • People who experience severe claustrophobia (extreme fear of enclosed spaces).
  • Women who are currently pregnant or breastfeeding, and women who do not agree to use reliable contraception or to avoid sexual activity for 24 hours after receiving the flortaucipir injection.
  • People who are currently taking part in another research study (outside of the DIAN study) that involves an active study medication, investigational drug, device, imaging agent, or placebo within the past 30 days before screening and throughout this trial up to 2 weeks after any study-related procedures.
  • People who have taken part in other research studies (outside of the DIAN study) involving radioactive agents within the past 12 months, if that participation would cause their total research-related radiation exposure in a given year to exceed limits set by US federal regulations (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2021
Est. completion
1 January 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

F 18 T807 Standard Uptake Value Ratios (SUVR) will be correlated with other imaging modalities (MRI, PET amyloid imaging) and cognitive performance.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov